The Medical Letter on Drugs and Therapeutics
Denosumab (Prolia) for Postmenopausal Osteoporosis
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved use of denosumab (Prolia – Amgen) for treatment of osteoporosis in postmenopausal women at high risk for fracture.

MECHANISM OF ACTION — Denosumab is a fully human anti-RANK ligand antibody that inhibits the proliferation, differentiation and maturation of preosteoclasts into active bone-resorbing cells. It decreases bone remodeling and increases bone mineral density.

PHARMACOLOGY — Following subcutaneous (SC) injection, serum concentrations of denosumab reach a maximum in 10 days and remain high enough to inhibit bone turnover for at least 6 months. By 9 months they fall below the effective range.

CLINICAL STUDIES — In a randomized, double-blind trial in 7808 women with postmenopausal osteoporosis, 60 mg of denosumab injected SC every 6 months for 3 years reduced the incidence of vertebral fracture compared to placebo from 7.2% to 2.3%, ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Denosumab (Prolia) for Postmenopausal Osteoporosis
Article code: 1349a
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian